Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 677Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
QUALITY
Year : 2013  |  Volume : 4  |  Issue : 2  |  Page : 144-147

Fraud and misconduct in clinical research: A concern


Sr. CRA Group Head, Novartis Health Care Private Limited, Sandoz House, Worli, Mumbai, India

Correspondence Address:
Ashwaria Gupta
Sr. CRA Group Head, Novartis Health Care Private Limited, 5th Floor,Sandoz House, Shiv Sagar Estate, Dr. Annie Besant Road, Worli, Mumbai
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2229-3485.111800

Rights and Permissions

Fraud and misconduct in clinical research is widespread. Good clinical practice is a guideline adopted internationally as standard operating procedure for conduct of clinical research. Despite these guidelines being available, unavailability of internationally harmonized framework for managing research fraud and misconduct makes clinical research a highly vulnerable area to commit fraud. Fraud could be of various types and due to various reasons. Whatever the circumstances be, any fraud should be dealt with strictly and regulations should be in place to prevent its occurrence.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed4630    
    Printed90    
    Emailed3    
    PDF Downloaded786    
    Comments [Add]    
    Cited by others 11    

Recommend this journal